TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00657202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
Study: NCT01281969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamunex Intravenous Immunoglobulin
Description: 2.0 gm/kg total, IV (in the vein), over 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, IV (in the vein), over 2 days
Study: NCT04688073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Running

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Running

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: sit and rest
Study: NCT03525431

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Exome Sequencing
Description: Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
Study: NCT03929757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY
Description: Participants will receive 0.5 mL IM injection of MenACWY.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: Participants will receive 0.5 mL IM injection of MenACWY.
Study: NCT02457169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Preschool Engagement intervention
Description: This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
Study: NCT04308161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D oral gel
Description: vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D oral gel
Description: vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Topical Gel
Description: topical anti fungal agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Topical Gel
Description: topical anti fungal agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracure gel
Description: Topical analgesic gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oracure gel
Description: Topical analgesic gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkamisr sachets
Description: Sodium bicarbonate mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkamisr sachets
Description: Sodium bicarbonate mouthwash
Study: NCT02743026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOXY
Description: This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
Study: NCT02035644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinlida granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo granules
Study: NCT01741896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic preconditioning
Description: The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
Study: NCT03928132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPD Workshop on Depression and Diabetes
Description: 2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CPD Workshop on Depression and Diabetes
Description: 2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
Study: NCT01243190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
Study: NCT01561404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
Study: NCT03234699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 2 mg midazolam syrup (Days 7, 69, 105)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Pill
Description: 5 mg (Days 7 and 105)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Pill
Description: 20 mg (Days 7 and 105)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Pill
Description: 150 mg (Days 1 and 99)
Study: NCT03868995

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Dextrose water injection to subcutaneous layer at tender point

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tendon injection
Description: Dextrose water injection to injured tendon
Study: NCT03600233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVM-1118
Description: Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.
Study: NCT03002870

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients will receive questionnaires yearly to follow their QOL
Study: NCT01822301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeat Fat grafting
Description: Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
Study: NCT06106932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
Study: NCT04793659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Fasudil 90 mg/day
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Fasudil 90 mg/day
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Fasudil 180 mg/day
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Fasudil 180 mg/day
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral tablet
Study: NCT00518466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 25 mg modified-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 25 mg modified-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 25 mg modified-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: 7.5 mg immediate-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: 7.5 mg immediate-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: 7.5 mg immediate-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 100 and 25 mg immediate-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: 37.5 and 7.5 mg immediate-release tablets
Study: NCT04463173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole
Description: single dose, oral administration 30 minutes after breakfast with high fat food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole
Description: single dose, oral administration before breakfast.
Study: NCT03204188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
Study: NCT03629639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI\>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI\>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
Study: NCT01249989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential MBC Condition
Description: Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous MBC Condition
Description: Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
Study: NCT02902874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT02570685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflective Interpersonal Gratitude
Description: Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for.....

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflective-Behavioral Gratitude
Description: Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Control Journal
Description: Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
Study: NCT04020354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: Early Hand and arm bimanual intensive therapy including lower extremities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual customary care
Study: NCT02731573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-PLEX
Description: D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open heart surgery
Description: Subject will undergo open heart surgery according to standard of care
Study: NCT01373021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2500mcg+NS50ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
Study: NCT01456637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Description: The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Description: The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
Study: NCT02458313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMXB-A
Description: 150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules b.i.d. for 12 weeks
Study: NCT00576706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide 100㎎, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 200㎍ 12 weeks
Study: NCT02012439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Study: NCT02825693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cataract surgery (phacoemulsification)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted cataract surgery
Study: NCT01043068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cancer pain management
Description: Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
Study: NCT02900729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation catheter
Description: Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, losartan potassium and hydrochlorothiazide
Description: Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine, losartan potassium and hydrochlorothiazide
Description: Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
Study: NCT02495506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold stored platelets
Description: Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature platelets
Description: Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.